Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer.

Hiller DJ, Meschonat C, Kim R, Li BD, Chu QD.

Surgery. 2011 Sep;150(3):459-65. doi: 10.1016/j.surg.2011.07.005.

PMID:
21878231
2.

Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.

Hiller DJ, Chu Q, Meschonat C, Panu L, Burton G, Li BD.

J Surg Res. 2009 Oct;156(2):265-9. doi: 10.1016/j.jss.2009.03.060. Epub 2009 May 3.

PMID:
19665145
3.

Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.

Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.

Surgery. 2009 Aug;146(2):220-6. doi: 10.1016/j.surg.2009.05.010.

PMID:
19628077
4.

Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer.

Kleiner HE, Krishnan P, Tubbs J, Smith M, Meschonat C, Shi R, Lowery-Nordberg M, Adegboyega P, Unger M, Cardelli J, Chu Q, Mathis JM, Clifford J, De Benedetti A, Li BD.

J Exp Clin Cancer Res. 2009 Jan 9;28:5. doi: 10.1186/1756-9966-28-5. Erratum in: J Exp Clin Cancer Res. 2009;28:54.

5.

A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.

Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC, Li BD.

Ann Surg Oncol. 2008 Nov;15(11):3207-15. doi: 10.1245/s10434-008-0086-9. Epub 2008 Aug 22.

PMID:
18719964
6.

eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival.

Siegele B, Cefalu C, Holm N, Sun G, Tubbs J, Meschonat C, Odaka Y, DeBenedetti A, Ghali GE, Chu Q, Mathis JM, Li BD.

J Surg Res. 2008 Jul;148(1):83-9. doi: 10.1016/j.jss.2008.03.011. Epub 2008 Apr 9.

PMID:
18570935
7.

Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.

Byrnes KW, DeBenedetti A, Holm NT, Luke J, Nunez J, Chu QD, Meschonat C, Abreo F, Johnson LW, Li BD.

J Am Coll Surg. 2007 May;204(5):925-33; discussion 933-4.

PMID:
17481512
8.

High eIF4E, VEGF, and microvessel density in stage I to III breast cancer.

Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson LW, Debenedetti A, Abreo F, Turnage RH, McDonald JC, Li BD.

Ann Surg. 2006 May;243(5):684-90; discussion 691-2.

9.

A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.

McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, Li BD.

Ann Surg. 2005 Oct;242(4):584-90; discussion 590-2.

10.

Cystatin m: a novel candidate tumor suppressor gene for breast cancer.

Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, Sloane BF, Miller FR, Meschonat C, Li BD, Abreo F, Keppler D.

Cancer Res. 2004 Oct 1;64(19):6957-64.

11.

TLK1B is elevated with eIF4E overexpression in breast cancer.

Norton KS, McClusky D, Sen S, Yu H, Meschonat C, Debenedetti A, Li BD.

J Surg Res. 2004 Jan;116(1):98-103.

PMID:
14732354
12.

Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.

Sorrells DL, Meschonat C, Black D, Li BD.

J Surg Res. 1999 Jul;85(1):37-42.

PMID:
10383835
13.

Competitive PCR to detect eIF4E gene amplification in head and neck cancer.

Sorrells DL, Ghali GE, Meschonat C, DeFatta RJ, Black D, Liu L, De Benedetti A, Nathan CO, Li BD.

Head Neck. 1999 Jan;21(1):60-5.

PMID:
9890352
14.

Detection of eIF4E gene amplification in breast cancer by competitive PCR.

Sorrells DL, Black DR, Meschonat C, Rhoads R, De Benedetti A, Gao M, Williams BJ, Li BD.

Ann Surg Oncol. 1998 Apr-May;5(3):232-7.

PMID:
9607624

Supplemental Content

Loading ...
Support Center